Clinical Trials Sponsored by The National Institute of Allergy and Infectious Diseases, United States

Total 3344 results

National Institute of Allergy and Infectious Diseases...
United States Department of Defense

Completed

Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults

HIV Infections

Uganda, Kenya, Tanzania
National Institute of Allergy and Infectious Diseases...
United Biomedical

Completed

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Allergan

Withdrawn

Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

HIV Infections
National Institute of Allergy and Infectious Diseases...
United States Agency for International Development (USAID)

Completed

Social and Economic Outcomes of HIV/AIDS Care and Treatment in HIV Infected South African Adults

HIV Infections

South Africa
National Institute of Allergy and Infectious Diseases...

Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

HIV

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Protocol CAUSE-03 / CHEETAH (CHEETAH)

Asthma

United States
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Congenital Cytomegalovirus Infection
National Institute of Allergy and Infectious Diseases...

Recruiting

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (LEADS)

Atopic Dermatitis

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Linezolid Dosing Strategies in Drug-Resistant TB

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant

Brazil, India, Kenya, Philippines, South Africa, Zimbabwe, Thailand, Haiti, Peru, Botswana
National Institute of Allergy and Infectious Diseases...

Recruiting

A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)

Dengue Fever

Brazil
National Institute of Allergy and Infectious Diseases...

Recruiting

Phase 2 Shigella Vaccine and Challenge

Immunisation | Shigella Infection

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

Monkeypox

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults

Schistosomiasis

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

H3N2 Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

COVID-19

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

Zika Virus Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

COVID-19

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

Rabies | Rabies Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

HIV Infections

United States, South Africa
National Institute of Allergy and Infectious Diseases...

Suspended

Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein

Ebola Virus Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

Gonorrhoea

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Pharmacokinetics of VT-1598

Coccidioidomycosis

United States
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Influenza Immunisation | Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Intravenous Fosfomycin Pharmacokinetics Study

Bacterial Infection | Pathogen Resistance | Multiple-drug Resistance

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis (VIBRANT)

Lupus Nephritis

United States
National Institute of Allergy and Infectious Diseases...

Completed

StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis

Tuberculosis | Pulmonary Tuberculosis

South Africa
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV

HIV-1-infection

United States
National Institute of Allergy and Infectious Diseases...

Terminated

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

Gastroenteritis Escherichia Coli | Immunisation

Bangladesh
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs

HIV Infections

South Africa, Uganda, Malawi, Zimbabwe
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children

RSV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine (CoVPN 3006)

SARS-CoV-2 Infection

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Placebo-Controlled Trial of Antibiotic Therapy in Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level

Lower Respiratory Tract Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females - A Sub-study of HPTN 084

HIV Infections

Zimbabwe, South Africa, Uganda
National Institute of Allergy and Infectious Diseases...

Completed

SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

Covid19 | SARS-CoV2 Infection

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

The Safety and Effectiveness of Different Doses of Vitamin C in HIV-Infected Patients

HIV Infections
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

HIV Infections

United States, Switzerland
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

HIV Infections

United States, Botswana, Brazil, Kenya, South Africa, Tanzania, Thailand, Zimbabwe
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy

HIV Infections

South Africa, Uganda, Malawi, Zimbabwe
National Institute of Allergy and Infectious Diseases...

Completed

Auranofin for Giardia Protozoa

Giardiasis | Amoebic Dysentery

Bangladesh
National Institute of Allergy and Infectious Diseases...

Completed

Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device

Immunisation | Hantavirus Pulmonary Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

Bacterial Infection

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)

Dysbiosis | Clostridial Infection | Probiotic Therapy

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis

HIV Infections | Tuberculosis

Peru, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Clinical Study of a Diagnostic Device for NG, TV and CT in Women

Gonococcal Infection | Trichomoniasis | Chlamydial Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

HIV Infections

United States, Puerto Rico

3

Subscribe